Appropriateness of statin prescription in the elderly

European Journal of Internal Medicine

Volumn 50, Issue , 2018, Pages 33-40

  Ruscica, M ^a   Macchi, C ^a   Pavanello, C ^a   Corsini, A ^a,b   Sahebkar, A ^c   Sirtori, C R ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

ALLHAT LLT; Elderly; HOPE 3; Myalgias; Statins; WOSCOPS

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CLINICAL DECISION MAKING; FRAIL ELDERLY; HEALTH; HUMAN; INFORMATION; META ANALYSIS; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; MYALGIA; MYOPATHY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHYSICIAN; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RISK; SECONDARY PREVENTION; AGED; BLOOD; CORONARY ARTERY DISEASE; MEDICATION COMPLIANCE; MORTALITY; PROCEDURES; RISK FACTOR;

AGED; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FRAIL ELDERLY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEDICATION ADHERENCE; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SECONDARY PREVENTION;

EID: 85039958673     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2017.12.011     Document Type: Review

References (82)

1. Sirtori, C.R., The pharmacology of statins. Pharmacol Res 88 (2014), 3–11.
2. Poli, A., Corsini, A., Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: analysis of SEAS and JUPITER trials. Eur J Intern Med 21 (2010), 372–373.
3. Banach, M., Aronow, W.S., Serban, C., Sahabkar, A., Rysz, J., Voroneanu, L. et al., Lipids, blood pressure and kidney update 2014. Pharmacol Res 95–96 (2015), 111–125.
4. Rich, M.W., Aggressive lipid management in very elderly adults: less is more. J Am Geriatr Soc 62 (2014), 945–947.
5. Nations WPA-tU.
6. Borsch-Supan, A., Brandt, M., Hunkler, C., Kneip, T., Korbmacher, J., Malter, F. et al., Data resource profile: the survey of health, ageing and retirement in Europe (SHARE). Int J Epidemiol 42 (2013), 992–1001.
7. Schwartz, J.B., Primary prevention: do the very elderly require a different approach?. Trends Cardiovasc Med 25 (2015), 228–239.
8. Cholesterol Treatment Trialists C, Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C. et al., Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
9. Rosengren, A., Better treatment and improved prognosis in elderly patients with AMI: but do registers tell the whole truth?. Eur Heart J 33 (2012), 562–563.
10. Pedro-Botet, J., Climent, E., Chillaron, J.J., Toro, R., Benaiges, D., Flores-Le Roux, J.A., Statins for primary cardiovascular prevention in the elderly. J Geriatr Cardiol 12 (2015), 431–438.
11. Piepoli, M.F., Hoes, A.W., Agewall, S., Albus, C., Brotons, C., Catapano, A.L. et al., 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37 (2016), 2315–2381.
12. McLean, A.J., Le Couteur, D.G., Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56 (2004), 163–184.
13. Jacobson, T.A., Overcoming ‘ageism’ bias in the treatment of hypercholesterolaemia: a review of safety issues with statins in the elderly. Drug Saf 29 (2006), 421–448.
14. Banach, M., Rizzo, M., Toth, P.P., Farnier, M., Davidson, M.H., Al-Rasadi, K. et al., Statin intolerance - an attempt at a unified definition. Position paper from an international lipid expert panel. Arch Med Sci 11 (2015), 1–23.
15. Chamberlin, K.W., Baker, W.L., Benefit-risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients. Clin Interv Aging 10 (2015), 733–740.
16. Stender, S., Budinski, D., Gosho, M., Hounslow, N., Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol 20 (2013), 40–53.
17. Martin, P.D., Dane, A.L., Nwose, O.M., Schneck, D.W., Warwick, M.J., No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 42 (2002), 1116–1121.
18. Gibson, D.M., Bron, N.J., Richens, A., Hounslow, N.J., Sedman, A.J., Whitfield, L.R., Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 36 (1996), 242–246.
19. Lim, W., Arnold, D.M., Bachanova, V., Haspel, R.L., Rosovsky, R.P., Shustov, A.R. et al., Evidence-based guidelines–an introduction. Hematology Am Soc Hematol Educ Program, 2008, 26–30.
20. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Bairey Merz, C.N., Blum, C.B., Eckel, R.H. et al., 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
21. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Bairey Merz, C.N., Blum, C.B., Eckel, R.H. et al., 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 129 (2014), S1–45.
22. Force, U.S.P.S.T., Bibbins-Domingo, K., Grossman, D.C., Curry, S.J., Davidson, K.W., Epling, J.W. Jr. et al., Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. JAMA 316 (2016), 1997–2007.
23. Jacobson, T.A., Maki, K.C., Orringer, C.E., Jones, P.H., Kris-Etherton, P., Sikand, G. et al., National lipid association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol 9 (2015), S1–122 [e1].
24. Catapano, A.L., Graham, I., De Backer, G., Wiklund, O., Chapman, M.J., Drexel, H. et al., 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37 (2016), 2999–3058.
25. Task Force M, Catapano, A.L., Graham, I., De Backer, G., Wiklund, O., Chapman, M.J. et al., 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 253 (2016), 281–344.
26. Housholder-Hughes, S.D., Martin, M.M., McFarland, M.R., Creech, C.J., Shea, M.J., Healthcare provider compliance with the 2013 ACC/AHA adult cholesterol guideline recommendation for high-intensity dose statins for patients with coronary artery disease. Heart Lung 46 (2017), 328–333.
27. Miettinen, T.A., Pyorala, K., Olsson, A.G., Musliner, T.A., Cook, T.J., Faergeman, O. et al., Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian simvastatin survival study (4S). Circulation 96 (1997), 4211–4218.
28. Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L. et al., Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2021–2031.
29. Shepherd, J., Blauw, G.J., Murphy, M.B., Bollen, E.L., Buckley, B.M., Cobbe, S.M. et al., Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002), 1623–1630.
30. Sever, P.S., Dahlof, B., Poulter, N.R., Wedel, H., Beevers, G., Caulfield, M. et al., Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial–lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003), 1149–1158.
31. Sever, P.S., Chang, C.L., Gupta, A.K., Whitehouse, A., Poulter, N.R., Investigators, A., The Anglo-Scandinavian cardiac outcomes trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J 32 (2011), 2525–2532.
32. Ridker, P.M., Group, J.S., Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108 (2003), 2292–2297.
33. Glynn, R.J., Koenig, W., Nordestgaard, B.G., Shepherd, J., Ridker, P.M., Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 152 (2010), 488–496 [W174].
34. Han, B.H., Sutin, D., Williamson, J.D., Davis, B.R., Piller, L.B., Pervin, H. et al., Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial. JAMA Intern Med 177 (2017), 955–965.
35. Colhoun, H.M., Betteridge, D.J., Durrington, P.N., Hitman, G.A., Neil, H.A., Livingstone, S.J. et al., Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004), 685–696.
36. Neil, H.A., DeMicco, D.A., Luo, D., Betteridge, D.J., Colhoun, H.M., Durrington, P.N. et al., Analysis of efficacy and safety in patients aged 65-75 years at randomization: collaborative atorvastatin diabetes study (CARDS). Diabetes Care 29 (2006), 2378–2384.
37. Ridker, P.M., Lonn, E., Paynter, N.P., Glynn, R., Yusuf, S., Primary prevention with statin therapy in the elderly: new meta-analyses from the contemporary JUPITER and HOPE-3 randomized trials. Circulation 135 (2017), 1979–1981.
38. Teng, M., Lin, L., Zhao, Y.J., Khoo, A.L., Davis, B.R., Yong, Q.W. et al., Statins for primary prevention of cardiovascular disease in elderly patients: systematic review and meta-analysis. Drugs Aging 32 (2015), 649–661.
39. Savarese, G., Gotto, A.M. Jr., Paolillo, S., D'Amore, C., Losco, T., Musella, F. et al., Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol 62 (2013), 2090–2099.
40. Cannon, C.P., Braunwald, E., McCabe, C.H., Rader, D.J., Rouleau, J.L., Belder, R. et al., Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004), 1495–1504.
41. Ray, K.K., Bach, R.G., Cannon, C.P., Cairns, R., Kirtane, A.J., Wiviott, S.D. et al., Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J 27 (2006), 2310–2316.
42. Deedwania, P., Stone, P.H., Bairey Merz, C.N., Cosin-Aguilar, J., Koylan, N., Luo, D. et al., Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the study assessing goals in the elderly (SAGE). Circulation 115 (2007), 700–707.
43. Chaturvedi, S., Zivin, J., Breazna, A., Amarenco, P., Callahan, A., Goldstein, L.B. et al., Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology 72 (2009), 688–694.
44. Heart Protection Study Collaborative G. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002), 7–22.
45. Heart Protection Study Collaborative G. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 378 (2011), 2013–2020.
46. Rothschild, D.P., Novak, E., Rich, M.W., Effect of statin therapy on mortality in older adults hospitalized with coronary artery disease: a propensity-adjusted analysis. J Am Geriatr Soc 64 (2016), 1475–1479.
47. Stone, N.J., Intwala, S., Katz, D., Statins in very elderly adults (debate). J Am Geriatr Soc 62 (2014), 943–945.
48. Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L. et al., Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388 (2016), 2532–2561.
49. Rodriguez, F., Maron, D.J., Knowles, J.W., Virani, S.S., Lin, S., Heidenreich, P.A., Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol 2 (2017), 47–54.
50. Ofori-Asenso, R., Jakhu, A., Zomer, E., Curtis, A.J., Korhonen, M.J., Nelson, M. et al., Adherence and persistence among statin users aged 65 years and over: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci, 2017, 10.1093/gerona/glx169 (Sep 2.).
51. Hickson, R.P., Robinson, J.G., Annis, I.E., Killeya-Jones, L.A., Korhonen, M.J., Cole, A.L. et al., Changes in statin adherence following an acute myocardial infarction among older adults: patient predictors and the association with follow-up with primary care providers and/or cardiologists. J Am Heart Assoc, 6, 2017.
52. Vallejo-Vaz, A.J., Robertson, M., Catapano, A.L., Watts, G.F., Kastelein, J.J., Packard, C.J. et al., Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (west of Scotland coronary prevention study) 5-year randomized trial and 20-year observational follow-up. Circulation 136 (2017), 1878–1891.
53. Kashef, M.A., Giugliano, G., Legacy effect of statins: 20-year follow up of the west of Scotland coronary prevention study (WOSCOPS). Glob Cardiol Sci Pract, 2016, 2016, e201635.
54. Ford, I., Shah, A.S., Zhang, R., McAllister, D.A., Strachan, F.E., Caslake, M. et al., High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. J Am Coll Cardiol 68 (2016), 2719–2728.
55. Gulliford, M., Ravindrarajah, R., Hamada, S., Jackson, S., Charlton, J., Inception and deprescribing of statins in people aged over 80 years: cohort study. Age Ageing 46 (2017), 1001–1005.
56. Mallery, L.H., Moorhouse, P., Respecting frailty. J Med Ethics 37 (2011), 126–128.
57. Kutner, J.S., Blatchford, P.J., Taylor, D.H. Jr., Ritchie, C.S., Bull, J.H., Fairclough, D.L. et al., Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med 175 (2015), 691–700.
58. Ravnskov, U., Diamond, D.M., Hama, R., Hamazaki, T., Hammarskjold, B., Hynes, N. et al., Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open, 6, 2016, e010401.
59. Petersen, L.K., Christensen, K., Kragstrup, J., Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80 +− year olds. Age Ageing 39 (2010), 674–680.
60. Postmus, I., Deelen, J., Sedaghat, S., Trompet, S., de Craen, A.J., Heijmans, B.T. et al., LDL cholesterol still a problem in old age? A Mendelian randomization study. Int J Epidemiol 44 (2015), 604–612.
61. Prospective Studies, C., Lewington, S., Whitlock, G., Clarke, R., Sherliker, P., Emberson, J. et al., Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370 (2007), 1829–1839.
62. Weverling-Rijnsburger, A.W., Blauw, G.J., Lagaay, A.M., Knook, D.L., Meinders, A.E., Westendorp, R.G., Total cholesterol and risk of mortality in the oldest old. Lancet 350 (1997), 1119–1123.
63. Newson, R.S., Felix, J.F., Heeringa, J., Hofman, A., Witteman, J.C., Tiemeier, H., Association between serum cholesterol and noncardiovascular mortality in older age. J Am Geriatr Soc 59 (2011), 1779–1785.
64. Bellosta, S., Corsini, A., Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf, 2017, 1–13.
65. Bruckert, E., Hayem, G., Dejager, S., Yau, C., Begaud, B., Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther 19 (2005), 403–414.
66. Magni, P., Macchi, C., Morlotti, B., Sirtori, C.R., Ruscica, M., Risk identification and possible countermeasures for muscle adverse effects during statin therapy. Eur J Intern Med 26 (2015), 82–88.
67. Stroes, E.S., Thompson, P.D., Corsini, A., Vladutiu, G.D., Raal, F.J., Ray, K.K. et al., Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J 36 (2015), 1012–1022.
68. Mansi, I., Frei, C.R., Pugh, M.J., Makris, U., Mortensen, E.M., Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern Med 173 (2013), 1–10.
69. Corsini, A., The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc Drugs Ther 17 (2003), 265–285.
70. Armitage, J., The safety of statins in clinical practice. Lancet 370 (2007), 1781–1790.
71. Tompkins, R., Schwartzbard, A., Gianos, E., Fisher, E., Weintraub, H., A current approach to statin intolerance. Clin Pharmacol Ther 96 (2014), 74–80.
72. Bays, H., Cohen, D.E., Chalasani, N., Harrison, S.A., The National Lipid Association's Statin Safety Task F. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol 8 (2014), S47–57.
73. Richardson, K., Schoen, M., French, B., Umscheid, C.A., Mitchell, M.D., Arnold, S.E. et al., Statins and cognitive function: a systematic review. Ann Intern Med 159 (2013), 688–697.
74. Rojas-Fernandez, C.H., Goldstein, L.B., Levey, A.I., Taylor, B.A., Bittner, V., The National Lipid Association's Safety Task F. An assessment by the Statin Cognitive Safety Task Force: 2014 update. J Clin Lipidol 8 (2014), S5–16.
75. Rosenson, R.S., Baker, S., Banach, M., Borow, K.M., Braun, L.T., Bruckert, E. et al., Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol 70 (2017), 1290–1301.
76. Ruscica, M., Baldessin, L., Boccia, D., Racagni, G., Mitro, N., Non-insulin anti-diabetic drugs: an update on pharmacological interactions. Pharmacol Res 115 (2017), 14–24.
77. Ruscica, M., Macchi, C., Morlotti, B., Sirtori, C.R., Magni, P., Statin therapy and related risk of new-onset type 2 diabetes mellitus. Eur J Intern Med 25 (2014), 401–406.
78. Brown, F., Singer, A., Katz, A., Konrad, G., Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. Can Fam Physician 63 (2017), e495–e503.
79. Mallery, L.H., Moorhouse, P., McLean Veysey, P., Allen, M., Fleming, I., Severely frail elderly patients do not need lipid-lowering drugs. Cleve Clin J Med 84 (2017), 131–142.
80. Camerino, G.M., De Bellis, M., Conte, E., Liantonio, A., Musaraj, K., Cannone, M. et al., Statin-induced myotoxicity is exacerbated by aging: a biophysical and molecular biology study in rats treated with atorvastatin. Toxicol Appl Pharmacol 306 (2016), 36–46.
81. Mohaupt, M.G., Karas, R.H., Babiychuk, E.B., Sanchez-Freire, V., Monastyrskaya, K., Iyer, L. et al., Association between statin-associated myopathy and skeletal muscle damage. CMAJ 181 (2009), E11–8.
82. Odden, M.C., Pletcher, M.J., Coxson, P.G., Thekkethala, D., Guzman, D., Heller, D. et al., Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States. Ann Intern Med 162 (2015), 533–541.